LTP with attenuated androgens and tranexamic acid was administered in 52% and 20% of symptomatic patients with HAE Type 1/2, respectively; 7% and 18% of patients with nC1‐INH‐HAE with mutation in F12 gene, respectively; 14% and 28% of patients with nC1‐INH‐HAE with unknown mutation, respectively. A total of 5 patients from these groups used C1‐INH for LTP. The gene discussed is SERPING1; the disease is hereditary angioedema.